Literature DB >> 19207971

The history of the "natural history" of hepatitis C (1968-2009).

Leonard B Seeff1.   

Abstract

In the late 1960's, only types A and B hepatitis were believed to exist, distinguished by circumstances of exposure and incubation periods. In the early 1970's, studies of transfusion recipients were begun with the belief that hepatitis B would be responsible should transfusion-associated hepatitis develop. After discovery of the viruses of hepatitis A and B, neither agent was found responsible, hence non-A, non-B (NANB) hepatitis. Initial follow-up of these cases showed that approximately 50% developed chronic hepatitis based on persistence of serum enzymes for at least 6 months. Approximately 15 years later, after the hepatitis C virus had been identified as the cause for NANB hepatitis, chronic hepatitis was found to develop more frequently as indicated by persistent viral infection in over 80% of infected adults but in only about 50% of infected children or young women. Follow-up over 2 to 4 decades indicated that many infected persons developed progressive hepatic fibrosis, sometimes culminating in cirrhosis and/or liver cancer. Long-term natural history studies have proved to be challenging because disease onset is often silent and progression extremely slow. Differing strategies have been used to determine the natural history, the descriptions and results of which are presented in this review.

Entities:  

Mesh:

Year:  2009        PMID: 19207971      PMCID: PMC4373556          DOI: 10.1111/j.1478-3231.2008.01927.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  102 in total

1.  Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection.

Authors:  S Krugman; J P Giles; J Hammond
Journal:  JAMA       Date:  1967-05-01       Impact factor: 56.272

2.  Strategies for assessing the long-term consequences of Hepatitis C virus infection.

Authors:  L B Seeff
Journal:  Minerva Gastroenterol Dietol       Date:  2000-12

3.  Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.

Authors:  M Vogt; T Lang; G Frösner; C Klingler; A F Sendl; A Zeller; B Wiebecke; B Langer; H Meisner; J Hess
Journal:  N Engl J Med       Date:  1999-09-16       Impact factor: 91.245

4.  Evidence for viral hepatitis other than type A or type B among persons in Costa Rica.

Authors:  V M Villarejos; K A Visoná; C A Eduarte; P J Provost; M R Hilleman
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

5.  The long-term pathological evolution of chronic hepatitis C.

Authors:  M Yano; H Kumada; M Kage; K Ikeda; K Shimamatsu; O Inoue; E Hashimoto; J H Lefkowitch; J Ludwig; K Okuda
Journal:  Hepatology       Date:  1996-06       Impact factor: 17.425

6.  Morbidity and mortality in paid Austrian plasma donors infected with hepatitis C at plasma donation in the 1970s.

Authors:  Peter Ferenci; Stefan Ferenci; Christian Datz; Ingo Rezman; Wilhelm Oberaigner; Reinhild Strauss
Journal:  J Hepatol       Date:  2007-02-15       Impact factor: 25.083

7.  Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study.

Authors:  A Sangiovanni; R Morales; G Spinzi; M Rumi; A Casiraghi; R Ceriani; E Colombo; M Fossati; A Prada; E Tavani; G Minoli
Journal:  Hepatology       Date:  1998-03       Impact factor: 17.425

8.  Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

Authors:  C Niederau; S Lange; T Heintges; A Erhardt; M Buschkamp; D Hürter; M Nawrocki; L Kruska; F Hensel; W Petry; D Häussinger
Journal:  Hepatology       Date:  1998-12       Impact factor: 17.425

9.  Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth.

Authors:  Maria Antonietta Casiraghi; Massimo De Paschale; Luisa Romanò; Renato Biffi; Agnese Assi; Giorgio Binelli; Alessandro Remo Zanetti
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

10.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245

View more
  72 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  How do persistent infections with hepatitis C virus cause liver cancer?

Authors:  Jonathan K Mitchell; Stanley M Lemon; David R McGivern
Journal:  Curr Opin Virol       Date:  2015-09-29       Impact factor: 7.090

3.  N 6-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling.

Authors:  Geon-Woo Kim; Hasan Imam; Mohsin Khan; Aleem Siddiqui
Journal:  J Biol Chem       Date:  2020-07-27       Impact factor: 5.157

Review 4.  Regulation of hepatic innate immunity by hepatitis C virus.

Authors:  Stacy M Horner; Michael Gale
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

5.  Recommendations on hepatitis C screening for adults.

Authors:  Roland Grad; Brett Thombs; Marcello Tonelli; Maria Bacchus; Richard Birtwhistle; Scott Klarenbach; Harminder Singh; Veronique Dorais; Nathalie Holmes; Wendy Martin; Rachel Rodin; Alejandra Jaramillo Garcia
Journal:  CMAJ       Date:  2017-04-24       Impact factor: 8.262

Review 6.  Insights into antiviral innate immunity revealed by studying hepatitis C virus.

Authors:  Stacy M Horner
Journal:  Cytokine       Date:  2015-03-25       Impact factor: 3.861

7.  Predicting cirrhosis and clinical outcomes in patients with advanced chronic hepatitis C with a panel of genetic markers (CRS7).

Authors:  Teresa M Curto; Robert J Lagier; Anna S Lok; James E Everhart; Charles M Rowland; John J Sninsky
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

Review 8.  Mechanisms of hepatocarcinogenesis in chronic hepatitis C.

Authors:  Jonathan K Mitchell; David R McGivern
Journal:  Hepat Oncol       Date:  2014-09-09

Review 9.  Mortality and morbidity among military personnel and civilians during the 1930s and World War II from transmission of hepatitis during yellow fever vaccination: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

10.  Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis.

Authors:  Max Trubnikov; Ping Yan; Jane Njihia; Chris Archibald
Journal:  CMAJ Open       Date:  2014-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.